Trial
NCT07181382
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase IIISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
GB002, Inc.
Collaborators
Chiesi Farmaceutici S.p.A.
Condition
Pulmonary Hypertension Associated With Interstitial Lung Disease
Intervention
Placebo
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-19